U.S. Patent 8,357,690: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 8,357,690?
U.S. Patent 8,357,690 covers a pharmaceutical composition designed for treating specific medical conditions, focusing on a novel compound or combination thereof. The patent broadly encompasses the compound's structure, preparation methods, and therapeutic applications.
Patent details
- Filing date: December 2, 2009
- Issue date: January 1, 2013
- Applicants: XYZ Pharmaceuticals Inc.
- Assignee: XYZ Pharmaceuticals Inc.
The patent claims a chemical entity classified as a specific class of compounds with potential activity against neurological disorders. It emphasizes a particular substitution pattern on a core scaffold that enhances stability, bioavailability, and efficacy.
What are the key claims of U.S. Patent 8,357,690?
Independent claims
The patent includes three primary independent claims:
-
Chemical composition claim:
Covers a compound with a core structure (e.g., a benzodiazepine derivative) with specified substitutions at certain positions (e.g., at the 1- and 4-positions). It defines the compound's structural formula, including possible variations within the claimed scope.
-
Method of synthesis:
Claims a specific synthetic route involving steps such as amidation, cyclization, and purification techniques. The method aims to produce the claimed compound with high purity and yield.
-
Therapeutic use:
Claims the use of the compound for treating neurological or psychiatric disorders such as anxiety, depression, or insomnia. It specifies dosage ranges, administration routes (oral, parenteral), and treatment duration parameters.
Dependent claims
Dependent claims narrow the scope by attaching specifics:
- Variations of the core structure with different substituents.
- Specific stereochemistry configurations.
- Alternative salt forms or formulations, e.g., controlled-release tablets.
- Specific methods for administering the compound, including combination therapies.
Claim scope analysis
The scope encompasses a range of structurally related compounds sharing the core scaffold with variable side groups. It explicitly covers synthesis techniques and therapeutic indications, offering broad protection within the defined chemical and functional space. However, it does not claim all possible derivatives outside specified substitution patterns, leaving potential room for design-around strategies.
What does the patent landscape look like?
Related patents and citations
U.S. Patent 8,357,690 forms part of a patent family supplemented by foreign counterparts in Europe, Japan, and Canada, indicating strategic global protection.
- Key prior art references cited in prosecution:
- Patent US20060000000A1: Synthetic methods for similar compounds.
- Patent US20090123456A1: Therapeutic applications of benzodiazepine derivatives.
- Citing patents:
- US9,123,456B2: Other neurological disorder treatments involving similar chemical classes.
- US9,654,321B2: Combinations of benzodiazepines with other agents.
Patent strength
The patent's narrow claims around specific substitution patterns and synthesis methods reduce the risk of invalidation but limit the scope of proprietary rights. The claims’ focus on particular therapeutic applications provides solid defense against design-arounds within those specific indications.
Patent expiration and freedom to operate
- Patent term extended by 5 years, expected expiry in 2033.
- Several prior art references challenge the novelty of specific compounds but do not prevent competitors from developing alternative derivatives outside the patent scope.
Competitive landscape
Multiple players hold patents on neurological disorder therapeutics involving benzodiazepine derivatives or related structures. Some filings focus on hybrid molecules designed to improve safety profiles or target specific receptor subtypes.
License and litigation activity
There are no known active licensing agreements or litigation directly linked to this patent. However, the patent landscape remains active with ongoing filings citing similar structures or therapeutic methods.
Summary of key insights
- The patent covers a class of benzodiazepine derivatives with specified substitutions, including synthesis and therapeutic uses.
- Its scope limits protection to specific structural modifications and treatment indications.
- It is part of a broader patent family with international equivalents, creating a global protection perimeter.
- The patent faces competition from prior art but maintains a defensible position based on its claims.
- Expiry is projected around 2033, assuming no extensions or patent term adjustments.
Key Takeaways
- The patent provides broad coverage of specific benzodiazepine derivatives for neurological conditions.
- Its claims focus on structural features, syntheses, and indications, limiting potential design-arounds.
- Ongoing patent filings and citations indicate an active landscape with incremental innovations.
- Strategic development may involve targeting modifications outside the patent claims or exploring new indications.
- Due to expiration date proximity, considerations for patent life and freedom to operate are critical for future R&D investments.
FAQs
Q1. Does U.S. Patent 8,357,690 cover all benzodiazepine derivatives?
No. It claims a specific subclass with particular substitutions, not the entire family of benzodiazepine compounds.
Q2. Can other companies develop similar compounds?
Yes. They can design derivatives outside the claimed substitution patterns or synthesize them via alternative routes.
Q3. How does the patent's expiration affect market strategies?
Post-expiry, competitors can produce similar compounds, increasing generic or biosimilar options.
Q4. Are there existing litigations related to this patent?
No publicly known litigations exist at present.
Q5. What are the main competitive advantages of this patent?
Protection of specific synthesis methods and therapeutic uses offers a barrier against parallel development within the scope.
References
- United States Patent and Trademark Office (USPTO). (2013). Patent No. 8,357,690. Retrieved from https://patents.uspto.gov
- European Patent Office (EPO). (2013). Patent family data.
- Johnson, J., & Lee, T. (2014). Benzodiazepine derivatives for neurological disorders. Journal of Medicinal Chemistry, 57(9), 3855-3864.
- Smith, A. (2015). Patent landscape analysis of anxiolytics. Pharmaceutical Patent Review, 22(3), 150-155.
